Filippo de Marinis
About
Filippo de Marinis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Filippo de Marinis has authored 450 papers receiving a total of 19.0k indexed citations (citations by other indexed papers that have themselves been cited), including 392 papers in Pulmonary and Respiratory Medicine, 330 papers in Oncology and 63 papers in Molecular Biology. Recurrent topics in Filippo de Marinis's work include Lung Cancer Treatments and Mutations (362 papers), Lung Cancer Research Studies (182 papers) and Lung Cancer Diagnosis and Treatment (160 papers). Filippo de Marinis is often cited by papers focused on Lung Cancer Treatments and Mutations (362 papers), Lung Cancer Research Studies (182 papers) and Lung Cancer Diagnosis and Treatment (160 papers). Filippo de Marinis collaborates with scholars based in Italy, United States and Spain. Filippo de Marinis's co-authors include Joachim von Pawel, U. Gatzemeier, Giorgio V. Scagliotti, Keunchil Park, Christian Manegold, Antonio Passaro, Jose R. Pereira, Cesare Gridelli, Tony Mok and Johan Vansteenkiste and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.
In The Last Decade
Filippo de Marinis
436 papers receiving 18.5k citations
Hit Papers
Peers
Filippo de Marinis
Vera Hirsh Canada
Silvia Novello Italy
Tudor–Eliade Ciuleanu Romania
Nobuyuki Yamamoto Japan
Isamu Okamoto Japan
Johan Vansteenkiste Belgium
Sumitra Thongprasert Thailand
Lucio Crinò Italy
Sai‐Hong Ignatius Ou United States
Shirish M. Gadgeel United States
Citations per year, relative to Filippo de Marinis Filippo de Marinis (= 1×)
peers
Vera Hirsh
Countries citing papers authored by Filippo de Marinis
Since
Specialization
Citations
This map shows the geographic impact of Filippo de Marinis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo de Marinis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo de Marinis more than expected).
Fields of papers citing papers by Filippo de Marinis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Filippo de Marinis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo de Marinis. The network helps show where Filippo de Marinis may publish in the future.
Co-authorship network of co-authors of Filippo de Marinis
This figure shows the co-authorship network connecting the top 25 collaborators of Filippo de Marinis. A scholar is included among the top collaborators of Filippo de Marinis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filippo de Marinis. Filippo de Marinis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fabrizio, Federico Pio, Ilaria Attili, & Filippo de Marinis. (2024). Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art. Cancers. 16(7). 1331–1331.
2.
Solomon, Benjamin, Yi‐Long Wu, Rafał Dziadziuszko, et al.. (2024). 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo). Annals of Oncology. 35. S775–S775.
3.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology. 42(29). 3400–3409.
4.
Aliaga, Pamela Trillo, Ester Del Signore, Gianluca Spitaleri, et al.. (2024). The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics. Genes. 15(6). 701–701.
5.
Attili, Ilaria, Gianluca Spitaleri, Carla Corvaja, et al.. (2024). Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials. Cancers. 16(13). 2457–2457.
6.
Spitaleri, Gianluca, Pamela Trillo Aliaga, Ilaria Attili, et al.. (2024). Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”. Cancers. 16(16). 2877–2877.
7.
Yang, James Chih‐Hsin, Jong Seok Lee, Yun Fan, et al.. (2023). Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.. Journal of Clinical Oncology. 41(17_suppl). LBA9000–LBA9000.
8.
Nadal, Ernest, Valentina Guarneri, Marie Wislez, et al.. (2023). 1358P Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC. Annals of Oncology. 34. S780–S781.
9.
Herbst, Roy S., Daniel Ruderman, James F. Conway, et al.. (2023). OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell Scoring on SP263-Stained Whole Imaging Slides from IMpower110. Journal of Thoracic Oncology. 18(11). S79–S80.
10.
Lococo, Filippo, Alessandra Cancellieri, Marco Chiappetta, et al.. (2023). Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results. Clinical Lung Cancer. 24(5). 467–473.
11.
Borghaei, Hossein, Melissa L. Johnson, Edward B. Garon, et al.. (2023). LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S1308–S1308.
12.
Garassino, Marina Chiara, Willemijn S.M.E. Theelen, Robert M. Jotte, et al.. (2023). LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Annals of Oncology. 34. S1309–S1310.
13.
Reck, Martin, Ana Laura Ortega Granados, Filippo de Marinis, et al.. (2023). 1468P Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial. Annals of Oncology. 34. S832–S833.
14.
Spitaleri, Gianluca, Pamela Trillo Aliaga, Ilaria Attili, et al.. (2023). MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target. Cancers. 15(19). 4779–4779.
15.
Passaro, Antonio, Silvia Novello, Diana Giannarelli, et al.. (2021). Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers. 13(12). 2935–2935.
16.
Wolf, Jennifer Moriatis, Tobias R. Overbeck, Ji‐Youn Han, et al.. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Kölner Universitäts PublikationsServer (Universität zu Köln).
17.
Gainor, Justin F., Daniel Shao-Weng Tan, Benjamin Solomon, et al.. (2015). Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clinical Cancer Research. 21(12). 2745–2752.
18.
Scagliotti, Giorgio V., Cesare Gridelli, Filippo de Marinis, et al.. (2014). Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. Lung Cancer. 85(3). 408–414.
19.
Pirker, Robert, Jose R. Pereira, Joachim von Pawel, et al.. (2011). EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. The Lancet Oncology. 13(1). 33–42.
20.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Vera Hirsh Breakdown of academic impact, for papers by Silvia Novello Breakdown of academic impact, for papers by Tudor–Eliade Ciuleanu Breakdown of academic impact, for papers by Nobuyuki Yamamoto Breakdown of academic impact, for papers by Isamu Okamoto Breakdown of academic impact, for papers by Johan Vansteenkiste Breakdown of academic impact, for papers by Sumitra Thongprasert Breakdown of academic impact, for papers by Lucio Crinò Breakdown of academic impact, for papers by Sai‐Hong Ignatius Ou Breakdown of academic impact, for papers by Shirish M. Gadgeel